Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The LuMEn Study: 177Lu-octreotate Treatment Outcome Prediction Using Multimodality Imaging in Refractory Neuroendocrine Tumours.

NCT01842165 is registered in ClinicalTrials.gov with Jules Bordet Institute as lead sponsor.

NCT NCT01842165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01842165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The LuMEn Study: 177Lu-octreotate Treatment Outcome Prediction Using Multimodality Imaging in Refractory Neuroendocrine Tumours.
Lead sponsor
Jules Bordet Institute
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2013
Completion date
September 19, 2022
Enrollment
37 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastroenteropancreatic neuroendocrine tumors